Improving Your A-Game: Mastering Vaccine Guidelines, Timing, and Administration in the IBD Patient

Gastroenterology
Curriculum:
IBD Institute
Credits:
0.5 AMA PRA Category 1 Credit(s)™
Launch Date:
31-Jul-18
Expiration Date:
31-Jul-19

Primary Audience:

This activity is designed to meet the educational needs of gastroenterologists, internists, family medicine and primary care physicians, nurse practitioners, and physician assistants who provide care to patients with IBD.

Relevant Terms:

Vaccinations, IBD, ACG Preventive Guideline, ACIP and CDC Vaccination Guidelines

Gary R. Lichtenstein, MD

Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA

Michael Cirigliano, MD, FACP

Michael Cirigliano, MD, FACP
Founder's Associate Professor of General Internal Medicine
Perelman School of Medicine at the
University of Pennsylvania
Philadelphia, PA

1. Assess vaccination status and routine preventive care needs in patients with IBD in accordance with recommended schedules
2. Individualize vaccination recommendations in alignment with current guidelines to help mitigate the risk of vaccine-preventable infection in patients with IBD
3. Implement strategies that increase the frequency of guideline-compliant vaccination schedule completion for each IBD patient prior to initiating therapy
4. Coordinate responsibilities for vaccination recommendations, monitoring, and administration among clinicians that care for patients with IBD

Estimated Time to Complete
30-minutes
 
Activity Overview
Patients with IBD are at an increased risk for infections, however, some of these infections are preventable by vaccination. While immunocompetent IBD patients can generally be vaccinated using standard immunization recommendations, there are special considerations for IBD patients receiving immunosuppressive therapy; this is especially important when treatment includes biological therapies. The use of immunosuppressive therapy will influence vaccine recommendations and preventive care counseling by gastroenterologists and the primary care team.
 
Using interactive case scenarios, Gary R. Lichtenstein, MD and Michael Cirigliano, MD, will explore vaccine-related issues that are relevant to patients with IBD being treated with immunosuppressive biological therapies.
 
Joint Providers
Jointly Provided by   and  
 
Joint Accreditation Statement
 In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and peerXchange.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
To contact PIM please email information@pimed.com
 
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
 
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
 
Gary R. Lichtenstein, MD
Professor of Medicine
Director, Center for Inflammatory Bowel Diseases
The Raymond and Ruth Perelman School of Medicine of the University of Pennsylvania
Hospital of the University of Pennsylvania
Gastroenterology Division, Department of Internal Medicine
Perelman Center for Advanced Medicine
Philadelphia, PA
 
Consulting: Abbvie, Actavis, Alaven, CellCeutrix, Celgene, Ferring, Gilead, Hospira, Janssen Biotech, Luitpold/American Regent, Pfizer Pharmaceuticals, Prometheus Laboratories, Inc., Romark, Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, Takeda, UCB
 
Contracted Research: Celgene, Janssen Biotech, Salix Pharmaceuticals/Valeant, Santarus/Receptos/Celgene, Shire Pharmaceuticals, UCB
 
Other (Honorarium): Clinical Advances in Gastroenterology (Editor), Gastro-Hep Communications (Editor), Ironwood (CME Program), Luitpold/American Regent (CME Program), Merck (CME Program), McMahon Publishing (Author), Romark (CME), Springer Science and Business Media (Editor), Up-To-Date (Author)
 
Funding to University of Pennsylvania: Janssen Biotech (IBD Fellow Education), Pfizer Pharmaceuticals (IBD Fellow Education), Takeda (IBD Fellow Education)
 
Royalty: SLACK, Inc. (Book Royalty)
 
Michael Cirigliano, MD, FACP
Founder's Associate Professor of General Internal Medicine
Perelman School of Medicine at the
University of Pennsylvania
Philadelphia, PA
 
Fees for Non-CME/CE Services Received Directly from a Commercial Supporter: Medical Contributor, Fox29 News
 
Planning Committee
The PIM planners and managers have nothing to disclose. The peerXchange planners and managers have nothing to disclose.
 
Method of Participation
There are no fees to participate in the enduring activity. During the period July 31, 2018 through July 31, 2019, participants must 1) read the CME information, including learning objectives and facul­ty disclosures; 2) study the educational activity; and 3) complete the pre-test, post-test and evaluation form. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, submit and your post-test will automatically be graded. Once you successfully complete the post-test (score of 70% or greater) and activity evaluation, your Statement of Credit will be made available immediately to view or print for your records.
 
Copyright Statement
© 2018. This CME-certified activity is held as copyrighted © by peerXchange. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).
 
Media
Internet
 
COURSE VIEWING REQUIREMENTS
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6+ for Mac OSX 10.7 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above